Vogenx Inc (VOGX US)
VOGX US$18.92
20 minute delayed
14 days free access
Join Market Matters and get full access to all our Opinion + Action
Performance
Advanced charting functionality with the ability to amend timeframes, chart type & indicator selection, powered by TradingView.
Share price activity
Displays share price activity. Volume = number of shares traded, Turnover = value of shares traded, VWAP = volume-weighted average price for the day, sourced from Morningstar.
- Last (Price)
- 18.92
- Change
- ▼ -0.24 (-1.25)
- Bid / Ask
- 16.01 - 19.01
- Volume
- 22,836
- Turnover
- 220,125
- Open
- 18.60
- Day Range
- 18.39 - 19.55
- VWAP
- 18.91
- Prev Close
- 19.16
- Last Trade
- 28/10 4:00pm
Key information
Displays key information on the security, sourced from Morningstar.
- Sector
- Healthcare
- Shares Issued
- 14,855,087
- NTA/Share
- —
- Last Dividend
- —
- Dividend Ex Date
- —
- Dividend Pay Date
- —
Current (USD) · FY2025
Displays key financial data for the most recent fiscal year, in millions. Note - Per share data is in local currency terms irrespective of reporting currency, and may be different to the stated currency, sourced from Morningstar.
- Revenue
- 0.00
- EBITDA
- -1.45
- Profit
- -1.45
- Earnings Per Share (EPS)
- -0.19
- Dividend Per Share (DPS)
- —
- Yield %
- 0.00
- Market Cap
- 281.06
- Price to Earnings Ratio (P/E)
- -159.20
Estimates (AUD)
Displays consensus analyst’s estimates for key measures for the next fiscal year, sourced from Morningstar.
No consensus estimates are available for this company.
Quantitative rating
Displays Morningstar’s Quantitative Equity Research Rating for the security: a star rating from 1 (overvalued) to 5 (undervalued) from the share price against a fair value estimated by a statistical model of Morningstar’s analyst ratings, with the model’s economic moat, financial health and fair value uncertainty, sourced from Morningstar.
Overvalued
- Economic Moat
- Narrow
- Uncertainty
- Very High
Morningstar Quantitative Rating as of 23 OCT 2026.
Quantitative Equity Rating Methodology – view here
Fair value estimate
Displays Morningstar’s quantitative fair value estimate for the security against the current share price, with the band around it: the five-star price below which the model would rate the stock five stars and the one-star price above which it would rate it one star, sourced from Morningstar.
Five-star price 6.20 Fair value 15.01 One-star price 36.35
Morningstar Quantitative Rating as of 23 OCT 2026.
Quantitative valuation
Displays where the share price sits in Morningstar’s quantitative fair value band, from the five-star price (undervalued) to the one-star price (overvalued), with the fair value estimate, the price to fair value ratio, the model’s valuation label and its uncertainty rating, sourced from Morningstar.
Buy
Sell
- Fair Value
- 15.01
- Price / Fair Value
- 1.16
- Valuation
- Overvalued
- Uncertainty
- Very High
Morningstar Quantitative Rating as of 23 OCT 2026. The slider runs from the five-star price (6.20) to the one-star price (36.35).
Displays useful ratios for the security, NB the pricing date used, sourced from Morningstar.
| Ratios |
|---|
| Currency (Price/reporting): USD/USD |
| Exchange Rate: 1.0000 |
Price, volume and trading statistics for the security, sourced from Morningstar.
| Price - closing or last bid | 17.45 |
| Price - 12 month high | 36.92 |
| Price - 12 month low | 13.00 |
| Pricing date | 22 OCT 2026 |
| Volume - avg. trading volume for the last ten days | 0.10 |
| Market capitalization | 259.22 |
| 12 Month High price date | 18 SEP 2026 |
| 12 Month Low price date | 12 AUG 2026 |
| Volume - avg. trading volume for the last 3 months | 0.17 |
| Price - 1 Day % Change | -8.54% |
| Price - 13 week price percent change | — |
| Price - 26 week price percent change | — |
| Price - 5 Day % Change | 20.10% |
| Price - 52 week price percent change | — |
| Price - YTD price percent change | — |
| Price % Change Month To Date | -35.03% |
Earnings, dividends, cash flow and book value per share, sourced from Morningstar.
| EPS excluding extraordinary items - most recent fiscal year | -0.190 |
| EPS excluding extraordinary items - trailing 12 month | -0.217 |
| EPS Normalized - most recent fiscal year | -0.194 |
| Revenue/share - most recent fiscal year | 0.000 |
| Revenue/share - trailing 12 month | 0.000 |
| Book value per share - most recent fiscal year | — |
| Book value per share - most recent quarter | -0.128 |
| Book value (tangible) per share - most recent fiscal year | — |
| Book value (tangible) per share - most recent quarter | -0.128 |
| Cash per share - most recent fiscal year | — |
| Cash per share - most recent quarter | 0.014 |
| Cash Flow per share - most recent fiscal year | -0.185 |
| Cash Flow per share - trailing 12 month | -0.204 |
| Dividend per share - most recent fiscal year | — |
| Dividends per share - trailing 12 month | 0.000 |
| EBITD per share - trailing 12 month | -0.216 |
| EPS Basic excluding extraordinary items - most recent fiscal year | -0.190 |
| EPS Basic excluding extraordinary items - trailing 12 month | -0.217 |
| EPS including extraordinary items - most recent fiscal year | -0.190 |
| EPS including extraordinary items - trailing 12 month | -0.217 |
| Free Cash Flow per share - trailing 12 month | -0.204 |
Valuation multiples such as P/E, price to sales, price to book and enterprise value ratios, sourced from Morningstar.
| P/E excluding extraordinary items, most recent fiscal year | — |
| P/E Normalized, most recent fiscal year | — |
| Price to sales - most recent fiscal year | — |
| Price to Tangible Book - most fiscal year | — |
| Price to Free Cash Flow per Share - most recent fiscal year | — |
| Price to Cash Flow per share - trailing 12 month | — |
| Price to Book - most recent fiscal year | — |
| P/E excluding extraordinary items high, trailing 12 months | — |
| P/E excluding extraordinary items low, trailing 12 months | — |
| Net Debt, LFI | 0.67 |
| Net Debt, LFY | 0.22 |
| Dividend Yield - 5 Year Average | — |
| Dividend Yield - indicated annual dividend divided by closing price | — |
| Current Dividend Yield - Common Stock Primary Issue, LTM | 0.00% |
Cash flow, liquidity and leverage measures, sourced from Morningstar.
| Free Cash Flow - most recent fiscal year | -1.42 |
| LT debt/equity - most recent fiscal year | — |
| Payout ratio - most recent fiscal year | — |
| Total debt/total equity - most recent fiscal year | — |
| LT debt/equity - most recent quarter | — |
| Total debt/total equity - most recent quarter | — |
| Free Cash Flow - trailing 12 month | -1.56 |
| Payout ratio - trailing 12 month | — |
Key income statement lines for the most recent fiscal year, in millions, sourced from Morningstar.
| Revenue - most recent fiscal year | 0.00 |
| Revenue - trailing 12 month | 0.00 |
| EBITD - most recent fiscal year | -1.45 |
| EBITD - trailing 12 month | -1.66 |
| Earnings before taxes - most recent fiscal year | -1.45 |
| Earnings before taxes - trailing 12 month | -1.65 |
| Net Income available to common - most recent fiscal year | -1.45 |
| Net Income available to common - trailing 12 months | -1.65 |
| Earnings before taxes Normalized - most recent fiscal year | -1.48 |
| Net Income Available to Common, Normalized - most recent fiscal year | — |
| Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding, TTM | -0.21 |
Profitability margins for the most recent fiscal year, sourced from Morningstar.
| Net Profit Margin % - 1st historical fiscal year | — |
| Net Profit Margin % - trailing 12 month | — |
| Operating margin - 1st historical fiscal year | — |
| Operating margin - trailing 12 month | — |
| Pretax margin - trailing 12 month | — |
| Pretax margin - 1st historical fiscal year | — |
| Operating Margin - 5 year average | — |
| Pretax Margin - 5 year average | — |
| Free Operating Cash Flow/Revenue, 5 Year Average | — |
| Free Operating Cash Flow/Revenue, TTM | — |
| Net Profit Margin - 5 year average | — |
Returns on average assets and equity for the fiscal year, the trailing 12 months and as 5 year averages, and net income and revenue per employee in whole currency, sourced from Morningstar.
| Return on average assets - most recent fiscal year | -175.06% |
| Return on average assets - trailing 12 month | -166.03% |
| Return on average equity - most recent fiscal year | — |
| Return on average equity - trailing 12 month | — |
| Return on average assets - 5 year average | — |
| Return on average equity - 5 year average | — |
| Net Income/employee - most recent fiscal year | — |
| Revenue/employee - most recent fiscal year | — |
Growth in revenue, earnings, dividends and book value over recent periods, sourced from Morningstar.
| Revenue growth rate, 5 year | — |
| EPS growth rate, 5 year | — |
| Growth rate% - dividend, 3 year | — |
| Revenue/share (5 yr growth) | — |
| Growth rate% - Revenue, 3 year | — |
| Growth rate% - EPS, 3 year | — |
| Book value per share growth rate, 5 year | — |
| Capital Spending growth rate, 5 year | — |
| Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR | — |
Displays analyst’s forecasts for key measures. The estimates can be expanded to see the spread of the calls. Full lines = reported, and dotted lines are forward estimates. Click a measure to add or remove it from the chart, sourced from Morningstar.
Financial forecast (AUD, millions except per share)
No consensus estimates are available for this company.
Financial metrics can be plotted on the graph to see trends. Multiple metrics from multiple statements can be plotted against each other, sourced from Morningstar.
Financials (USD, millions)
| Period end: | DEC 24 | DEC 25 |
| Fiscal year: | 2024 | 2025 |
| Period length: | 12 months | 12 months |
Displays all company announcements released by the company to the exchange, sourced from Morningstar.
Announcements
Announcements are available for ASX-listed companies only.
Opinion
No opinions for this company yet.
Action
No actions for this company yet.
Business Summary
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
Relevant suggested news and content from the site
Video
WATCH
Webinar Recording: Are commodities entering a Supercycle?
Recorded Wednesday 24th June @ 12.30pm
Podcast
LISTEN
Thursday 11th September – Dow off -220pts, SPI off -20pts
Daily Podcast Direct from the Desk
Video
WATCH
Buy Hold Sell: The 6 income stocks readers love, plus 2 expert ideas
Recorded 10th June 2026
Podcast
LISTEN
Wednesday 10th September – Dow up +196pts, SPI down -4pts
Daily Podcast Direct from the Desk
